Abstract: Osimertinib, as a representative of the third generation epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI), has significant curative effect for EGFR T790M mutation type non-small cell lung cancer (NSCLC). But with the development of clinical research Osimertinib's resistance gradually appear. How to deal with the resistance is a problem that the clinical workers must focus on. This article will review the latest research progress of the mechanisms and the solutions of osimertinib acquired resistance.

Key words: Osimertinib, non-small cell lung cancer, acquired resistance, research progress